Kawasaki disease

Yonsei Medical Journal

Volumn 47, Issue 6, 2006, Pages 759-772

  Kim, Dong Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Kawasaki disease

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; INFLUENZA VACCINE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; TICLOPIDINE; ULINASTATIN; WARFARIN;

ADD ON THERAPY; AGE DISTRIBUTION; CERVICAL LYMPHADENOPATHY; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; CORONARY ARTERY ANEURYSM; DIAGNOSTIC TEST; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; ERYTHEMA; FEVER; GASTROINTESTINAL IRRITATION; HEART INFARCTION; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; LIMB; LIP; LIVER DYSFUNCTION; LOW DRUG DOSE; MONOTHERAPY; MOUTH MUCOSA; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; RASH; REVIEW; REYE SYNDROME; SINGLE DRUG DOSE; SUDDEN DEATH; VASCULITIS;

EID: 33845921764     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2006.47.6.759     Document Type: Review

References (126)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Arerugi 1967;16:178-222.
2. Yamamoto T, Oya T, Watanabe A, et al. Clinical features of Kawasaki disease [in Japanese]. Shonika Rinsho (Jpn J Pediatr) 1968;21:291-7.
3. Kosaki F, Kawasaki T, Okawa S, et al. Clinicopathological conference on 10 fatal cases with acute febrile mucocutaneous lymph node syndrome [in Japanese]. Shonika Rinsho (Jpn J Pediatr) 1971;24:2545-59.
4. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6.
5. Burns JC, Wiggins JW Jr, Toews WH, Newburger JW, Leung DY, Wilson H, et al. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr 1986;109:759-63.
6. Suddleson EA, Reid B, Woolley MM, Takahashi M. Hydrops of the gallbladder associated with Kawasaki syndrome. J Pediatr Surg 1987;22:956-9.
7. Roh TW, Park MC, Kim DS. Antibody response against 65kD heat shock protein in Kawasaki disease [in Korean]. Pediatr Allergy Respir Dis 1993;3:68-72.
8. Kim HY, Kim DS, Shin JS. NRAMP1 Gene Expression in Patients with Kawasaki Disease [in Korean]. Pediatr Allergy Respir Dis 2000;10:153-60.
9. Kim HS, Noh GW, Kim DS, Lee KY, Lee HS, Lee HK, et al. Decreased CD5+ B cells during the acute phase of Kawasaki disease. Yonsei Med J 1996;37:52-8.
10. Kim HY, Lee HG, Kim DS. Apoptosis of peripheral blood mononuclear cells in Kawasaki disease. J Rheumatol 2000;27:801-6.
11. Dengler LD, Capparelli EV, Bastian JF, Bradley DJ, Glode MP, Santa S, et al. Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr Infect Dis J 1998;17:478-81.
12. Okada T, Harada K, Okuni M. Serum HDL-cholesterol and lipoprotein fraction in Kawasaki disease (acute mucocutaneous lymph node syndrome). Jpn Circ J 1982;46:1039-44.
13. Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation 1991;84:625-31.
14. Cabana VG, Gidding SS, Getz GS, Chapman J, Shulman ST. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 1997;42:651-5.
15. Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr 1995;126:524-9.
16. Momenah T, Sanatani S, Potts J, Sandor GC, Human DG, Patterson MW. Kawasaki disease in the older child. Pediatrics 1998;102:e7.
17. Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. J Pediatr 2000;137:250-2.
18. Yanagawa H, Nakamura Y, Yashiro M, Oki I, Hirata S, Zhang T, et al. Incidence survey of Kawasaki disease in 1997 and 1998 in Japan. Pediatrics 2001;107:E33.
19. Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 2003;112: 495-501.
20. Chang RK. The incidence of Kawasaki disease in the United States did not increase between 1988 and 1997. Pediatrics 2003;111:1124-5.
21. Park YW, Han JW, Park IS, Kim CH, Yun YS, Cha SH, et al. Epidemiologic picture of Kawasaki disease in Korea, 2000-2002. Pediatr Int 2005;47:382-7.
22. Yanagawa H, Nakamura Y, Yashiro M, Ojima T, Tanihara S, Oki I, et al. Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatrics 1998;102:E65.
23. Fujita Y, Nakamura Y, Sakata K, Hara N, Kobayashi M, Nagai M, et al. Kawasaki disease in families. Pediatrics 1989;84:666-9.
24. Harada F, Sada M, Kamiya T, Yanase Y, Kawasaki T, Sasazuki T. Genetic analysis of Kawasaki syndrome. Am J Hum Genet 1986;39:537-9.
25. Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics 1995;95:475-9.
26. Kaneko K, Obinata K, Katsumata K, Tawa T, Hosaka A, Yamashiro Y. Kawasaki disease in a father and daughter. Acta Paediatr 1999;88:791-2.
27. Bruckheimer E, Bulbul Z, McCarthy P, Madri JA, Friedman AH, Hellenbrand WE. Images in cardiovascular medicine. Kawasaki disease: coronary aneurysms in mother and son. Circulation 1998;97:410-1.
28. Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease in parents and children. Acta Paediatr 2003;92:694-7.
29. Abe J, Kotzin BL, Jujo K, Melish ME, Glode MP, Kohsaka T, et al. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA 1992;89:4066-70.
30. Kim DS, Han BH, Lee SK, Lee HK, Chwae YJ, Lee KY. Evidence for selection of 11 amino acid CDR3 domains in V kappa III-derived immunoglobulin light chains in Kawasaki disease. Scand J Rheumatol 1997;26:350-4.
31. Leung DY, Giorno RC, Kazemi LV, Flynn PA, Busse JB. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 1995;155:5018-21.
32. Leung DY, Meissner HC, Shulman ST, Mason WH, Gerber MA, Glode MP, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr 2002;140:742-6.
33. Choi IH, Chwae YJ, Shim WS, Kim DS, Kwon DH, Kim JD, et al. Clonal expansion of CD8+ T cells in Kawasaki disease. J Immunol 1997;159:481-6.
34. Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001;166:1334-43.
35. Lee JS, Park IH, Shin JS, Kim DS. Clonal Expansion of Peripheral B Cells in Kawasaki Disease [in Korean]. Pediatr Allergy Respir Dis 2002;12:299-314.
36. Shulman ST, Melish M, Inoue O, Kato H, Tomita S. Immunoglobulin allotypic markers in Kawasaki disease. J Pediatr 1993;122:84-6.
37. Takeuchi K, Yamamoto K, Kataoka S, Kakihara T, Tanaka A, Sato S, et al. High incidence of angiotensin I converting enzyme genotype II in Kawasaki disease patients with coronary aneurysm. Eur J Pediatr 1997; 156:266-8.
38. Ahn SY, Jang GC, Shin JS, Shin KM, Kim DS. Tumor necrosis factor-alpha levels and promoter polymorphism in patients with Kawasaki disease in Korea. Yonsci Med J 2003;44:1021-6.
39. Huang Y, Lee YJ, Chen MR, Hsu CH, Lin SP, Sung TC, et al. Polymorphism of transmembrane region of MICA gene and Kawasaki disease. Exp Clin Immunogenet 2000;17:130-7.
40. Tsukahara H, Hiraoka M, Saito M, Nishida K, Kobata R, Tsuchida S, et al. Methylenetetrahydrofolate reductase polymorphism in Kawasaki disease. Pediatr Int 2000;42:236-40.
41. Jibiki T, Terai M, Shima M, Ogawa A, Hamada H, Kanazawa M, et al. Monocyte chemoattractant protein 1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein 1 in Japanese patients with Kawasaki disease. Arthritis Rheum 2001;44:2211-12.
42. Sohn MH, Hur MW, Kim DS. Interleukin 6 gene promoter polymorphism is not associated with Kawasaki disease. Genes Immun 2001;2:357-62.
43. Quasney MW, Bronstein DE, Cantor RM, Zhang Q, Stroupe C, Shike H, et al. Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease. Pediatr Res 2001;49:686-90.
44. Ouchi K, Suzuki Y, Shirakawa T, Kishi F. Polymorphism of SLC11A1 (formerly NRAMP1) gene confers susceptibility to Kawasaki disease. J Infect Dis 2003;187: 326-9.
45. Nishimura S, Zaitsu M, Hara M, Yokota G, Watanabe M, Ueda Y, et al. A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. J Pediatr 2003;143:357-62.
46. Biezeveld MH, Kuipers IM, Geissler J, Lam J, Ottenkamp JJ, Hack CE, et al. Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Lancet. 2003;361:1268-70.
47. Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn 1991;41:785-97.
48. Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001;184:940-3.
49. Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH. Systemic arterial expression of matrix metallo-proteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003;23:576-81.
50. Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, et al. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 1988;48:247-51.
51. Maury CP, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med 1988;319:1670-1.
52. Kim DS. Serum interleukin-6 in Kawasaki disease. Yonsei Med J 1992;33:183-8.
53. Jang GC, Kim HY, Ahn SY, Kim DS. Raised serum interleukin 15 levels in Kawasaki disease. Ann Rheum Dis 2003;62:264-6.
54. Sohn MH, Noh SY, Chang W, Shin KM, Kim DS. Circulating interleukin 17 is increased in the acute stage of Kawasaki disease. Scand J Rheumatol 2003;32:364-6.
55. Jang GC, Lee SY, Kim DS. Changes of Serum Interleukin-18 Levels in Kawasaki Disease [in Korean]. Pediatr Allergy Respir Dis 2001;11:130-7.
56. Kim DS, Lee KY. Serum soluble E-selectin levels in Kawasaki disease. Scand J Rheumatol 1994;23:283-6.
57. Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, Baker SC, et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis 2000;182:1183-91.
58. Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 2001;125:340-4.
59. Wang CL, Wu YT, Liu CA, Lin MW, Lee CJ, Huang LT, et al. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics 2003;111:E140-7.
60. Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, et al. Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res 1998;44:596-9.
61. Wong M, Silverman ED, Fish EN. Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease. J Rheumatol 1997;24:1179-85.
62. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990; 56:29-36.
63. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr 1992;121:924-6.
64. Kim DS, Lee HK, Noh GW, Lee SI, Lee KY. Increased serum interleukin-10 level in Kawasaki disease. Yonsei Med J 1996;37:125-30.
65. Kim KC, Kim DS. The soluble interleukin 2 receptor levels in Kawasaki disease [in Korean]. J Korean Pediatr Soc 1992;35:1657-66.
66. Hwang DH, Han JW, Choi KM, Shin KM, Kim DS. Expression of Toll-like Receptor-2 on the Peripheral Blood Monocytes in Kawasaki Disease Patients [in Korean]. J Korean Pediatr Soc 2005;48:315-20.
67. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61.
68. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-8.
69. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7.
70. Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatr Jpn 1994;36:347-54.
71. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93.
72. Lee HK, Kim DS, Noh GW, Lee KY. Effects of intravenous immune globulin on the peripheral lymphocyte phenotypes in Kawasaki disease. Yorsei Med J 1996; 37:357-63.
73. Xu C, Poirier B, Van Huyen JP, Lucchiari N, Michel O, Chevalier J, et al. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am J Pathol 1998;153:1257-66.
74. Sawaji Y, Haneda N, Yamaguchi S, Kajino Y, Kishida K, Seto S, et al. Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications. Acta Paediatr Jpn 1998;40: 218-25.
75. Zhang T, Yanagawa H, Oki I, Nakamura Y. Factors relating to the cardiac sequelae of Kawasaki disease one month after initial onset. Acta Paediatr 2002;91: 517-20.
76. Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004;144:496-9.
77. Marasini M, Pongiglione G, Gazzolo D, Campelli A, Ribaldone D, Caponnetto S. Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities. Am J Cardiol 1991;68:796-7.
78. Pickering LK, Red Book. 2003 Report of the Committee on Infectious Diseases. Chicago (IL): American Academy of Pediatrics; 2003.
79. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
80. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999;135:465-9.
81. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003; 142:611-6.
82. Okada Y, Shinohara M, Kobayashi T, Inoue Y, Tomomasa T, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003;143:363-7.
83. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/ Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17: 1144-8.
84. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78.
85. Newburger JW. Kawasaki disease: who is at risk? J Pediatr 2000;137:149-52.
86. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128: 146-9.
87. Takagi N, Kihara M, Yamaguchi S, Tamura K, Yabana M, Tokita Y, et al. Plasma exchange in Kawasaki disease. Lancet 1995;346:1307.
88. Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis 2000;181:1101-9.
89. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808-10.
90. Kuijpers TW, Biezeveld M, Achterhuis A, Kuipers I, Lam J, Hack CE, et al. Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect. Pediatrics 2003;112:986-92.
91. Ahn SY, Kim DS. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand J Rheumatol 2005;34:136-9.
92. Lee MS, An SY, Jang GC, Kim DS. A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate. Yonsei Med J 2002;43:527-32.
93. O'Brien M, Parness IA, Neufeld EJ, Baker AL, Sundel RP, Newburger JW. Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. Pediatrics 2000; 105:E64.
94. Williams RV, Wilke VM, Tani LY, Minich LL. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002;109: E4
95. Suzuki A, Kamiya T, Kuwahara N, Ono Y, Kohata T, Takahashi O, et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 1986;7:3-9.
96. Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed MD, Ferrieri P, et al. Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994;89:916-22.
97. Akagi T, Kato H, Inoue O, Sato N, Imamura K. Valvular heart disease in Kawasaki syndrome: incidence and natural history. Am Heart J 1990;120:366-72.
98. Yoshikawa J, Yanagihara K, Owaki T, Kato H, Takagi Y, Okumachi F, et al. Cross-sectional echocardiographic diagnosis of coronary artery aneurysms in patients with the mucocutaneous lymph node syndrome. Circulation 1979;59:133-9.
99. Capannari TE, Daniels SR, Meyer RA, Schwartz DC, Kaplan S. Sensitivity, specificity and predictive value of two-dimensional echocardiography in detecting coronary artery aneurysms in patients with Kawasaki disease. J Am Coll Cardiol 1986;7:355-60.
100. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85.
101. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177-80.
102. Asai T. Diagnosis and prognosis of coronary artery lesions in Kawasaki disease. Coronary angiography and the conditions for its application (a score chart) [Japanese]. Nippon Rinsho 1983;41:2080-5.
103. Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986;108:388-92.
104. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991;33:805-10.
105. Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 1998; 81:1116-20.
106. Hwang DH, Sin KM, Choi KM, Choi JY, Sul JH, Kim DS. Statistical analysis of 1,000 cases of Kawasaki disease patients diagnosed at a single institute. Korean J Pediatr 2005;48:416-24.
107. Takahashi M, Mason W, Lewis AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 1987;75:387-94.
108. Fujiwara T, Fujiwara H, Hamashima Y. Size of coronary aneurysm as a determinant factor of the prognosis in Kawasaki disease: clinicopathologic study of coronary aneurysms. Prog Clin Biol Res 1987;250: 519-20.
109. Nakano H, Ueda K, Saito A, Nojima K. Repeated quantitative angiograms in coronary arterial aneurysm in Kawasaki disease. Am J Cardiol 1985;56:846-51.
110. Ishii M, Ueno T, Akagi T, Baba K, Harada K, Hamaoka K, et al. Guidelines for catheter intervention in coronary artery lesion in Kawasaki disease. Pediatr Int 2001;43:558-62.
111. Akagi T, Ogawa S, Ino T, Iwasa M, Echigo S, Kishida K, et al. Catheter interventional treatment in Kawasaki disease: a report from the Japanese Pediatric Interventional Cardiology Investigation group. J Pediatr 2000;137:181-6.
112. Kitamura S. The role of coronary bypass operation on children with Kawasaki disease. Coron Artery Dis 2002;13:437-47.
113. Checchia PA, Pahl E, Shaddy RE, Shulman ST. Cardiac transplantation for Kawasaki disease. Pediatrics 1997;100:695-9.
114. Kamiya T, Suzuki A, Ono Y. Angiographic follow-up study of coronary artery lesion in the cases with a history of Kawasaki disease-with a focus on the follow-up more than ten years after the onset of the disease. In: Kato H, editor. Kawasaki Disease. Proceedings of the 5th International Kawasaki Disease Symposium, Fukuoka, Japan, May 22-25, 1995. New York (NY): Elsevier Science; 1995. p.569-73.
115. Fujiwara T, Fujiwara H, Hamashima Y. Frequency and size of coronary arterial aneurysm at necropsy in Kawasaki disease. Am J Cardiol 1987;59:808-11.
116. Nakano H, Saito A, Ueda K, Nojima K. Clinical characteristics of myocardial infarction following Kawasaki disease: report of 11 cases. J Pediatr 1986; 108:198-203.
117. Tatara K, Kusakawa S. Long-term prognosis of giant coronary aneurysm in Kawasaki disease: an angiographic study. J Pediatr 1987;111:705-10.
118. Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986;108:923-7.
119. Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 1994;124:721-5.
120. Matsubara T, Umezawa Y, Tsuru S, Motohashi T, Yabuta K, Furukawa S. Decrease in the concentrations of transforming growth factor-beta 1 in the sera of patients with Kawasaki disease. Scand J Rheumatol 1997;26:314-7.
121. Lee TJ, Chun JK, Yeon SI, Shin JS, Kim DS. Increased serum levels of macrophage migration inhibitory factor in patients with Kawasaki disease. Scand J Rheumatol. In press 2006.
122. Leung DY, Collins T, Lapierre LA, Geha RS, Pober JS. Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon. J Clin Invest 1986;77:1428-35.
123. Mason WH, Jordan SC, Sakai R, Takahashi M, Bernstein B. Circulating immune complexes in Kawasaki syndrome. Pediatr Infect Dis 1985;4:48-51.
124. Culora GA, Moore IE. Kawasaki disease, Epstein-Barr virus and coronary artery aneurysms. J Clin Pathol 1997;50:161-3.
125. Burns JC, Glode MP, Clarke SH, Wiggins J Jr, Hathaway WE. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr 1984;105:206-11.
126. Nash MC, Shah V, Reader JA, Dillon MJ. Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies are not increased in Kawasaki disease. Br J Rheumatol 1995;34:882-7.